Effect of zinc on liver cirrhosis with hyperammonemia: A preliminary randomized, placebo-controlled double-blind trial

Nutrition

Volumn 30, Issue 11-12, 2014, Pages 1409-1414

  Katayama, Kazuhiro ^a   Saito, Masanori ^b   Kawaguchi, Takumi ^c   Endo, Ryujin ^d   Sawara, Kei ^d   Nishiguchi, Shuhei ^b   Kato, Akinobu ^e   Kohgo, Hiroshi ^f   Suzuki, Kazutomo ^g   Sakaida, Isao ^h   Ueno, Yoshiyuki ⁱ   Habu, Daiki ^j   Ito, Toshifumi ^k   Moriwaki, Hisataka ^l   Suzuki, Kazuyuki ^m  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e Morioka Municipal Hospital   (Japan)

^f ASAHIKAWA MEDICAL COLLEGE   (Japan)

^g DOKKYO MEDICAL UNIVERSITY   (Japan)

^h YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ YAMAGATA UNIVERSITY   (Japan)

^j Osaka Prefecture University   (Japan)

^k OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^l GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m MORIOKA UNIVERSITY   (Japan)

more..

Author keywords

Ammonia metabolism; Hepatic encephalopathy; Nutritional intervention; Trace element; Zinc acetate

Indexed keywords

AMMONIA; PLACEBO; ZINC; ZINC ACETATE; TRACE ELEMENT;

ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; HYPERAMMONEMIA; LIVER CIRRHOSIS; MALE; MULTICENTER STUDY; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; SUPPLEMENTATION; TREATMENT OUTCOME; ZINC BLOOD LEVEL; BLOOD; CLINICAL TRIAL; COMPLICATION; DEFICIENCY; DIET SUPPLEMENTATION; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMMONIA; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERAMMONEMIA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TRACE ELEMENTS; TREATMENT OUTCOME; ZINC; ZINC ACETATE;

EID: 84908145459     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.04.018     Document Type: Article

References (40)

1. Alberino F., Gatta A., Amodio P., Merkel C., Di Pascoli L., Boffo G., et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001, 17:445-450.
2. Christensen E., Schlichting P., Fauerholdt L., Gluud C., Andersen P.K., Juhl E., et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984, 4:430-435.
3. Tajika M., Kato M., Mohri H., Miwa Y., Kato T., Ohnishi H., et al. Prognostic valueof energy metabolism in patients with liver cirrhosis. Nutrition 2002, 18:229-234.
4. Fischer J.E., Baldessarini R.I. False neurotransmitter and hepatic failure. Lancet 1971, 2:75-80.
5. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
6. Katayama K. Ammonia and hepatic encephalopathy. Hepatol Res 2004, 30S:S71-S78.
7. Muto Y., Sato S., Watanabe A., Moriwaki H., Suzuki K., Kato A., et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-713.
8. Muto Y., Sato S., Watanabe A., Moriwaki H., Suzuki K., Kato A., et al. Overwight and obesity increase the risk for liver cancer in patients liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006, 35:204-214.
9. Kawaguchi T., Shiraishi K., Ito T., Suzuki K., Koreeda C., Ohtake T., et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol 2014, 12:1012-1018.
10. Plank L.D., Gane E.J., Peng S., Muthu C., Muthur S., Gillanders L., et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology 2008, 48:557-566.
11. Fargion S., Valenti L., Fracanzani A.L. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology 2010, 51:1119-1121.
12. Walravens P.A. Zinc metabolism and its implications in clinical medicine. West J Med 1979, 130:133-142.
13. Stamoulis I., Kouraklis G., Theocharis S. Zinc and the liver: an active interaction. Dig Dis Sci 2007, 52:1595-1612.
14. Marchesini G., Fabbri A., Bianchi G., Brizi M., Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996, 23:1084-1092.
15. Prasad A.S. Zinc: an overview. Nutrition 1995, 11:93-95.
16. Vallee B.L., Fulchuk K.H. The biochemical basis of zinc physiology. Physiol Rev 1993, 73:79-118.
17. Pabo C.O., Peisach E., Grant R.A. Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem 2001, 70:313-340.
18. Joazeiro C.A., Weissman A.M. Ring finger proteins: mediators of ubiquitin ligase activity. Cell 2000, 102:549-552.
19. Kadrmas J.L., Beckerle M.C. The Lim domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 2004, 5:920-931.
20. Vallee B.L. The function of methallothionein. Neurochem Int 1995, 27:23-33.
21. Eide D.J. The SLC39 family of metal ion transporter. Pflugers Arch 2004, 447:796-800.
22. Palmiter R.D., Huang L. Efflux and compartmentalization of zinc by members of the SLC30 family of solute carriers. Pflugers Arch 2004, 447:744-751.
23. 2+ transporters and Zn2+ homeostasis in neurons. Eur J Pharmacol 2003, 479:298-302.
24. Kambe T., Yamaguchi-Iwai Y., Sasaki R., Nagao M. Overview of mammalian zinc transpoters. Cell Mol Life Sci 2004, 61:298-302.
25. Ganss B., Jheon A. Zinc finger transcription factors in skeletal development. Crit Rev Oral Biol Med 2004, 15:282-297.
26. Licastro F., Mariani R.A., Faldella G., Carpene E., Guidicini G., Rangoni A., et al. Immune-endocrine status and celiac disease in children with Down's syndrome: relationships with zinc and cognitive efficiency. Brain Res Bull 2001, 55:313-317.
27. Prasad A.S. Zinc and immunity. Mol Cell Biochem 1998, 188:63-69.
28. Kitamura H., Morikawa H., Kamon H., Iguchi M., Hojyo S., Fukuda T., et al. Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function. Nat Immunol 2006, 7:971-977.
29. Chiba M., Katayama K., Takeda R., Morita R., Iwahashi K., Onishi Y., et al. Diuretics aggravate zinc deficiency in patients with liver cirrhosis by increasing zinc excretion in urine. Hepatol Res 2013, 43:365-373.
30. Van Der Rijt C.C., Schalm S.W., Schat H., Foeken K., De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991, 100:1114-1118.
31. Rabbani P., Prasad A. Plasma ammonia and liver ornithine transcarbamylase activity in zinc deficiency in humans. Am J Physiol 1978, 235:E203-E206.
32. Prasad A.S., Rabbani P., Abbasii A., Oberleas D., Fernandez-Madrid F., Ryan J. Experimental zinc deficiency in humans. Ann Intern Med 1978, 89:483-490.
33. Reding P., Duchateau J., Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984, 2:493-495.
34. Riggio O., Merli M., Capocaccia L., Caschra M., Zullo A., Pinto G., et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992, 16:785-789.
35. Hayashi M., Ikezawa K., Ono A., Okabayashi S., Hayashi Y., Shimizu S., et al. Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis. Hepatol Res 2007, 37:615-619.
36. Katayama K., Sakakibara M., Imanaka K., Ohkawa K., Matsunaga T., Naito M., et al. Effect of zinc supplementation in patients with type C liver cirrhosis. Open J Gastroenterology 2011, 1:22-28.
37. Riggio O., Ariosto F., Merli M., Caschera M., Zullo A., Balducci G., et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991, 36:1204-1208.
38. Tesdale G., Jennet B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974, 2:81-83.
39. Roberts E.A., Schilsky M.L. Diagnosis and treatment of Wilson Disease: an update. Hepatology 2008, 47:2089-2111. AASLD practice guideline.
40. Brewer G.J., Dick R.T., Johnson V.D., Brunberg J.A., Kluin K.J., Fink J.K. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998, 132:264-278.